ArticleClinical and translational medicine2021
The immune checkpoints storm in COVID-19: Role as severity markers at emergency department admission.
Abstract readLetter
In one paragraph
Article in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Peripheral blood immune cell subsets as non-invasive biomarkers of colorectal cancer stage, laterality, metastasis and survival.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Identification of a circulating immunological signature as a liquid biopsy approach for the diagnosis of endometriosis.Scientific reports · 2026Article
- Exploratory characterization of dynamic soluble programmed death-ligand 1 trajectories and their association with mortality in critical coronavirus disease 2019.Journal of intensive care · 2026Article
- Age-stratified circulating immune signatures reveal non-invasive biomarkers for colorectal cancer detection.Immunity & ageing : I & A · 2025Article
- A blood-based liquid biopsy analyzing soluble immune checkpoints and cytokines identifies distinct neuroendocrine tumors.Journal of experimental & clinical cancer research : CR · 2025Article
- Comprehensive immune profiling and predictive modelling of paediatric acute hepatitis of unknown aetiology from a Spanish cohort.Frontiers in immunology · 2025Article
- TIM3 in COVID-19; A potential hallmark?Heliyon · 2024Review
- An observational study investigating soluble immune checkpoints as indicators of severe COVID-19.Microbiology spectrum · 2024Observational
- Article
- Distinct soluble immune checkpoint profiles characterize COVID-19 severity, mortality and SARS-CoV-2 variant infections.Frontiers in immunology · 2024Article
- Lipoxin AFrontiers in immunology · 2024Article
- Endotoxin tolerance and trained immunity: breaking down immunological memory barriers.Frontiers in immunology · 2024Review
- SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.Cell death & disease · 2023Review
- The Impact of Colistin Resistance on the Activation of Innate Immunity by Lipopolysaccharide Modification.Infection and immunity · 2023Article
- Transcriptomic clustering of critically ill COVID-19 patients.The European respiratory journal · 2023Article
- Health influence of SARS-CoV-2 (COVID-19) on cancer: a review.Acta biochimica et biophysica Sinica · 2022Review
- Immune system-related soluble mediators and COVID-19: basic mechanisms and clinical perspectives.Cell communication and signaling : CCS · 2022Review
- Differential Immune Checkpoint and Ig-like V-Type Receptor Profiles in COVID-19: Associations with Severity and Treatment.Journal of clinical medicine · 2022Article
- Early Routine Biomarkers of SARS-CoV-2 Morbidity and Mortality: Outcomes from an Emergency Section.Diagnostics (Basel, Switzerland) · 2022Article
- Soluble Immune Checkpoints Are Dysregulated in COVID-19 and Heavy Alcohol Users With HIV Infection.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
José Avendaño-OrtizThe Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Roberto Lozano-RodríguezThe Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.ORCID 0000-0003-0093-9707
Alejandro Martín-QuirósEmergency Department and Emergent Pathology Research Group, IdiPAZ La Paz University Hospital, Madrid, Spain.
Verónica TerrónThe Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Charbel Maroun-EidTumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Karla Montalbán-HernándezThe Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Jaime Valentín-QuirogaThe Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Miguel Ángel García-GarridoEmergency Department and Emergent Pathology Research Group, IdiPAZ La Paz University Hospital, Madrid, Spain.
Elena Muñoz Del ValThe Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Álvaro Del Balzo-CastilloThe Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.
María PeinadoEmergency Department and Emergent Pathology Research Group, IdiPAZ La Paz University Hospital, Madrid, Spain.
Laura GómezEmergency Department and Emergent Pathology Research Group, IdiPAZ La Paz University Hospital, Madrid, Spain.ORCID 0000-0001-6460-0708
Carmen Herrero-BenitoEmergency Department and Emergent Pathology Research Group, IdiPAZ La Paz University Hospital, Madrid, Spain.
Carolina RubioThe Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.
José Carlos Casalvilla-DueñasThe Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Paloma Gómez-CampeloThe Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Alejandro Pascual-IglesiasThe Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Carlos Del FresnoThe Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.
Luis A AguirreThe Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.ORCID 0000-0003-0903-9385
Eduardo López-CollazoThe Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.ORCID 0000-0003-1957-877X
Funding
Ayuntamiento de MadridFundación Familia AlonsoFundación Mutua Madrileña COVID-19Fundación UriaReale SegurosSantander Bank
Abstract
PubMed holds no abstract for this paper.
Indexed as
BiomarkersCase-Control StudiesComorbidityCOVID-19Cytokine Release SyndromeEmergency Service, HospitalFemaleHumansImmune Checkpoint ProteinsMaleMortalityPatient AdmissionPrognosisSARS-CoV-2Severity of Illness IndexSpainBiomarkersImmune Checkpoint Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.